Identification of Novel Substrates for the Serine Protease HTRA1 in the Human RPE Secretome
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
PURPOSE. To define the role of the serine protease HTRA1 in age-related macular degeneration (AMD) by examining its expression level and identifying its potential substrates in the context of primary RPE cell extracellular milieu. METHODS. Primary RPE cell cultures were established from human donor eyes and screened for CFH, ARMS2, and HTRA1 risk genotypes by using an allele-discrimination assay. HTRA1 expression in genotyped RPE cells was determined by using real-time PCR and quantitative proteomics. Potential HTRA1 substrates were identified by incubating RPE-conditioned medium with or without human recombinant HTRA1. Selectively cleaved proteins were quantified by using the differential stable isotope labeling by amino acids in cell culture (SILAC) strategy. RESULTS. HTRA1 mRNA levels were threefold higher in primary RPE cells homozygous for the HTRA1 promoter risk allele than in RPE cells with the wild-type allele, which translated into a twofold increase in HTRA1 secretion by RPE cells with the risk genotype. A total of 196 extracellular proteins were identified in the RPE secretome, and only 8 were found to be selectively cleaved by the human recombinant HTRA1. These include fibromodulin with 90% cleavage, clusterin (50%), ADAM9 (54%), vitronectin (54%), and alpha2-macroglobulin (55%), as well as some cell surface proteins including talin-1 (21%), fascin (40%), and chloride intracellular channel protein 1 (51%). CONCLUSIONS. Recombinant HTRA1 cleaves RPE-secreted proteins involved in regulation of the complement pathway (clusterin, vitronectin, and fibromodulin) and of amyloid deposition (clusterin, alpha2-macroglobulin, and ADAM9). These findings suggest a link between HTRA1, complement regulation, and amyloid deposition in AMD pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ong, S.-E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., & Mann, M. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m200025-mcp200 · Cited by 5,574 · cited 1×
“SP, signal peptide domain (1-22) cleaved in mature secreted protein; IGFBP, insulin growth factor–binding protein domain (33-100); Kazal-like: Kazal-like domain, with a structure similar to that of Kazal-type serine protease inhibitors.”
MethodComplement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449 · cited 1×
“SP, signal peptide domain (1-22) cleaved in mature secreted protein; IGFBP, insulin growth factor–binding protein domain (33-100); Kazal-like: Kazal-like domain, with a structure similar to that of Kazal-type serine protease inhibitors.”
MethodComplement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424 · cited 3×
“CFH TT* 8(1) 3 1 TC† 4(1) 8(2) 2(1) CC‡ 1 2(1) 1(1)”
MethodHageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 3×
“GG (3) AG (3) AA (3) F o ld C ah n g e”
HTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration
DeWan, A., Liu, M., Hartman, S., Zhang, S. S.-M., Liu, D. T. L., Zhao, C., Tam, P. O. S., Chan, W. M., Lam, D. S. C., Snyder, M., et al. (2006) · Science · doi:10.1126/science.1133807 · Cited by 876
A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration
Yang, Z., Camp, N. J., Sun, H., Tong, Z., Gibbs, D., Cameron, D. J., Chen, H., Zhao, Y., Pearson, E., Li, X., et al. (2006) · Science · doi:10.1126/science.1133811 · Cited by 796
Susceptibility genes for age-related maculopathy on chromosome 10q26
Jakobsdottir, J., Conley, Y. P., Weeks, D. E., Mah, T. S., Ferrell, R. E., & Gorin, M. B. (2005) · The American Journal of Human Genetics · doi:10.1086/444437 · Cited by 470 · cited 1×
“SP, signal peptide domain (1-22) cleaved in mature secreted protein; IGFBP, insulin growth factor–binding protein domain (33-100); Kazal-like: Kazal-like domain, with a structure similar to that of Kazal-type serine protease inhibitors.”
MethodKanda, A., Chen, W., Othman, M., Branham, K. E. H., Brooks, M., Khanna, R., He, S., Lyons, R., Abecasis, G. R., & Swaroop, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703933104 · Cited by 441
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA
Fritsche, L. G., Loenhardt, T., Janssen, A., Fisher, S. A., Rivera, A., Keilhauer, C. N., & Weber, B. H. F. (2008) · Nature Genetics · doi:10.1038/ng.170 · Cited by 400 · cited 1×
“SP, signal peptide domain (1-22) cleaved in mature secreted protein; IGFBP, insulin growth factor–binding protein domain (33-100); Kazal-like: Kazal-like domain, with a structure similar to that of Kazal-type serine protease inhibitors.”
MethodImplications of the serine protease HtrA1 in amyloid precursor protein processing
Grau, S., Baldi, A., Bussani, R., Tian, X., Stefanescu, R., Przybylski, M., Richards, P., Jones, S. A., Shridhar, V., Clausen, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501823102 · Cited by 215 · cited 1×
“SP, signal peptide domain (1-22) cleaved in mature secreted protein; IGFBP, insulin growth factor–binding protein domain (33-100); Kazal-like: Kazal-like domain, with a structure similar to that of Kazal-type serine protease inhibitors.”
MethodLuibl, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25843 · Cited by 203 · cited 1×
“SP, signal peptide domain (1-22) cleaved in mature secreted protein; IGFBP, insulin growth factor–binding protein domain (33-100); Kazal-like: Kazal-like domain, with a structure similar to that of Kazal-type serine protease inhibitors.”
Method
Cited by
HTRA proteases: regulated proteolysis in protein quality control
Clausen, T., Kaiser, M., Huber, R., & Ehrmann, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3065 · Cited by 478
Dysfunctional autophagy in RPE, a contributing factor in age-related macular degeneration
Golestaneh, N., Chu, Y., Xiao, Y.-Y., Stoleru, G. L., & Theos, A. C. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.453 · Cited by 357
On phagocytes and macular degeneration
Guillonneau, X., Eandi, C. M., Paques, M., Sahel, J.-A., Sapieha, P., & Sennlaub, F. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.06.002 · Cited by 185
Beaufort, N., Scharrer, E., Kremmer, E., Lux, V., Ehrmann, M., Huber, R., Houlden, H., Werring, D., Haffner, C., & Dichgans, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418087111 · Cited by 145
Genetics of age-related macular degeneration: current concepts, future directions
DeAngelis, M. M., Silveira, A. C., Carr, E. A., & Kim, I. K. (2011) · Seminars in Ophthalmology · doi:10.3109/08820538.2011.577129 · Cited by 94
Metadata
- Authors
- An, E., Sen, S., Park, S. K., Gordish-Dressman, H., & Hathout, Y.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2010-07-01
- Volume
- 51
- Issue
- 7
- Pages
- 3379
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2023529356
- Cited by
- 117
- References
- 12
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.